soul trial oral semaglutide cardiovascular outcomes Reduces CV Events in T2DM β (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine π§ͺ T2DM + ASCVD/CKD π Oral semaglutide 14 mg vs placebo π Cardiovascular Outcomes, Safety, and Tolerability
Description
This makes the participation of dietitians and nutritionists in therapy that much more important, since they offer a realistic, low-cost, covered alternative to medical obesity therapy alone
Begin your personalized journey by taking our free assessment quiz
When someone is in a caloric deficit, their body can turn to muscle for energy
Plasma donation is done through a process called plasmapheresis
Theres a healthy pipeline for new GLP-1 drugs that will likely be more effective, have fewer side effects, and potentially be indicated for more conditions
